Japanese healthcare technology company finds synergy with Indian market and Medinippon’s network

April 27, 2026

Medinippon provides services from market study, sales & marketing effort, and approval by Ministry of Health, Govt of India (CDSCO) for successful business launch by Create Medic Japan, a company listed in Tokyo stock exchange

Please see details in the following article:

Create Medic Launch Ceremony

The launch ceremony of Indian subsidiary of Create Medic, Japan in Chennai, 15th April 2026; Hon’ble Consul General of Japan Mr. Muneo Takahashi delivering the Chief Guest’s address;

In the pic L>R: Mr. Kousuke Suto, GM-Create Medic India, Prof. Shyamkumar N. Keshava, Dept. of Interventional Radiology, CMC, Vellore, Mr. Osamu Imazawa, President, Create Medic Japan, Mr. Katsuaki Yamane, MD, Create Medic India & Dr. Rajappa Senthilkumar, Director, MediNippon Healthcare.

In the pic L>R: Prof. Shyamkumar Keshava (Prof. of Radiology, CMC Vellore), Mr. Muneo Takahashi (Hon`ble Consul General of Japan, Chennai, India), Mr. Osamu Imazawa (President, Create Medic Co Ltd, Japan), Mr. Katsuaki Yamane (Managing Director, Create Medic Pvt Ltd, India), Mr. Kousuke Suto (Director, Create Medic Pvt Ltd, India), Prof. S. Arumugam (Head, Institute of Sports Sciences, Sri Ramachandra Institute of Higher Education, Chennai, India), Dr. Rajappa Senthilkumar (Director, Create Medic Pvt Ltd, India) 

Vietnam’s Role in Asian Medical Tourism; NCRM & GN Corporation spearhead tech-transfer

October 29, 2025

Colorectal cancer, Lung Cancer and Liver Cancer patients report longer survival and improved quality of life after AIET cell therapy using NK cells and T Cells, presented in NCRM NICHE annual conference.

Please see details in the following BiopharmaAPAC article:

BiopharmaAPAC

DMI group of institutes in India, Tanzania, Malawi and Zambia to start basic to translational research

August 20, 2025

A MoU for translational research in managing corneal blindnesswas signed among Kanyakumari Medical Mission Research Center (KMMC), Muttom, a nodal institute of DMI foundation in southern most part of India, their associate St. Joseph University in Dar-Es-Salaam, Tanzania, GN Corporation, Japan, their associates NCRM & Medinippon, along with Be Well Hospitals, Chennai, India and Light and Light Ventures, London, UK. In Phases, a Centre of Excellence (CoE) for Regenerative Medicineto translate basic science developments to clinical solutions will be set up in KMMC taking technological guidance from Japanese physician-scientists.

St. Joseph University in Dar-Es-Salaam, Tanzania, DMI St. Eugene University in Lusaka, Zambia, DMI St. John the Baptist University, Mangochi, Malawi to jointly conduct academic and translational research with the CoE in KMMC to develop regenerative medicine solutions for managing locally prevalent healthcare problems.

Please visit below sites for related research papers;

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840311

https://doi.org/10.1080/02713683.2023.2180039

07 Apr 2025

The Bees-Haus method (Buccal epithelium Expanded and Encapsulated in Scaffold; Hybrid Approach to Urethral Stricture) of autologous buccal mucosal cell based therapy, earlier reported in India in collaboration with NCRM, has now moved to a clinical application in Japan.

Please visit Businesswire https://businesswire.com/news/home/20250330565540/en/ for more details.

Published in Nature Scientific Reports

01 Mar 2025

neu REFIX® exo-polysaccharide Beta glucan improves Dystrophin in diaphragm, IGF-1 and muscle regeneration markers CD44, MYH3 in Duchenne Muscular Dystrophy model in our research supported by Kochi University, Kyushu University of Medical Sciences and clinicians and scientists in India and Japan.

Please visit https://doi.org/10.1038/s41598-025-92258-4 for details of the study.

Sri Ramachandra Institute team triumphs in the FCQ of NCRM NICHE 2024

02 Dec 2024

Winners of the XIX Fujio Cup Quiz at NCRM NICHE 2024, Zainab Shabbir Rasheed and Saiganesh Venkatesan, posing with the Fujio Cup, joined by Mr. V.R. Venkataachalam, Chancellor, Sri Ramachandra Institute of Higher Education and Research – SRIHER, and Dr. A. Sumathy, Professor and Head, Department of Biomedical Sciences, SRIHER (Left).

A global recognition to our 16-year long research outcome!

30 Nov 2024

In the Genito-Urinary Reconstructive Surgeons (GURS) Masterclass 2024 conducted in United Kingdom, Dr Masayuki Shinchi　and Dr Akio Horiguchi presented the BEES-HAUS autologous cell therapy for male urethral stricture, and were awared the best poster prize.

The basic study started in 2008, through human and animal buccal tissue dervied cells cell culture standardization, pre-clinical and pilot clinical studies now having been recognised in the prestigious international forum, would add further strength to the team in moving forward to make this a routine clinical procedure to imporve the quality of life of patients ailing with urethral stricture.

Please see the link below for more details.

https://www.linkedin.com/feed/update/urn:li:activity:6969439001384558592

Clinical study results of Neu REFIX B-glucans & research updates by Dr. K. Raghavan

06 Oct 2024

Dr. Raghavan, Pediatric Neurologist and first author of the clinical study using Neu REFIX (https://www.sciencedirect.com/science/article/pii/S2667242123000556) gave an update on the ongoing research both clinical and pre-clinical (https://www.nature.com/articles/s41598-023-44330-0) and answered the questions by delegates.

Neu REFIX pre-clinical studies in mdx mice @ AOMC-JMS 2024

05 Oct 2024

Disease modifying approach in managing Duchenne Muscular Dystrophy with Neu REFIX Beta 1,3-1,6 Glucans was presented at the Joint Conference of The 22nd Annual Meeting of Asian and Oceanian Myology Center and The 10th Annual Meeting of Japan Muscle Society; 14, September 2024; Pre-clinical studies using mdx mice yielding reduction in inflammation and fibrosis and decline in fatigue explained; Available to watch in YouTube:

At International Conference in Yokohama, Japan

17 Aug 2024

Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical resection of malignant pancreatic tumor, which was presented at the ASCO® Breakthrough meeting in Yokohama, Japan.

IgA and CD209, markers of immunity enhanced while CA19-9, the marker of pancreatic cancer and CD44, that of cancer recurrence and severity, significantly reduced in patients who had Nichi BRITE, compared to the control group in the study by gastro-enterology surgeons and nutritional support team of Chikamori Hospital, Kochi, Japan.

Importantly, the mean survival improved after Nichi BRITE administration.

For further details, please visit our Businesswire press release.